The 24 references in paper I. Vasilieva A., A. Samoilova G., И. Васильева А., А. Самойлова Г. (2014) “Современные подходы к химиотерапии туберкулеза легких // Current approach to chemotherapy of pulmonary tuberculosis” / spz:neicon:pulmonology:y:2011:i:3:p:108-112

1
World Health Organization. Global tuberculosis control: a short update to the 2009 report. Geneva: World Health Organization, 2009.
(check this in PDF content)
2
Центральный научно-исследовательский институт организации и информатизации здравоохранения Министерства здравоохранения и социального развития Российской Федерации. Отраслевые показатели противотуберкулезной работы в 2008–2009 гг.: Статистические материалы. М.; 2010.
(check this in PDF content)
3
World Health Organization. Global tuberculosis control: epidemiology, strategy, financing. Geneva: World Health Organization; 2010.
(check this in PDF content)
4
Бастиан И., Порталс Ф.Туберкулез с множественной лекарственной устойчивостью. М.: Медицина и жизнь; 2003.
(check this in PDF content)
5
Grandjean L., Moore D. Tuberculosis in the developing world: recent advances in diagnosis with special consideration of Васильева И.А., Самойлова А.Г. Современные подходы к химиотерапии туберкулеза легких extensively drug-resistant tuberculosis (XDR-TB). Curr. Opin. Infect. Dis. 2008; 21 (5): 454–461.
(check this in PDF content)
6
Грядунов Д.А., Зименков Д.В., Михайлович В.М. и др. Те хнология гидрогелевых биочипов и ее применение в медицинской практике. Мед. алфавит 2009; 3: 10–14.
(check this in PDF content)
7
Кузьмин А.В., Васильева И.А., Черноусова Л.Н. Эффективность химиотерапии деструктивного туберкулеза легких, основанной на результатах экспресс-детекции лекарственной чувствительности к изониазиду и рифампицину тест-системой "ТБ\u000fБИОЧИП". Пробл. туб. и бол. легких 2006; 8: 17–23.
(check this in PDF content)
8
Исакова Ж.Т.Практическое значение тест-системы "ТБ\u000fбиочип MDR" в экспресс\u000fидентификации штам\u000f мов М. tuberculosis с множественной лекарственной устойчивостью. Клин. лаб. диагн. 2009; 2: 50–51.
(check this in PDF content)
9
Hillemann D., Rusch5Gerdes S., Richter E. Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J. Clin. Microbiol. 2007; 45 (8): 2635–2640.
(check this in PDF content)
10
Hillemann D., Rusch5Gerdes S., Richter E.Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacincapreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J. Clin. Microbiol. 2007; 47 (6): 1767–1772.
(check this in PDF content)
11
Balabanova Y., Drobniewski F., Nikolayevskyy V. еt al.An integrated approach to rapid diagnosis of tuberculosis and multidrug resistance using liquid culture and molecular methods in Russia. PLoS One 2009; 4 (9): e7129.
(check this in PDF content)
12
Brossier F., Veziris N., Aubry A. Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates. J. Clin. Microbiol. 2010; 48 (5): 1683–1689.
(check this in PDF content)
13
World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. Geneva: World Health Organization, 2008.
(check this in PDF content)
14
Caminero J., Sotgiu G., Zumla A. et al.Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect. Dis. 2010; 10: 621–629.
(check this in PDF content)
15
Boogaard J., Kibiki G., Kisanga E. et al.New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob. Agents Chemother. 2009; 53 (3): 849–862.
(check this in PDF content)
16
Migliori G.B., Lange C., Girardi E. et al. Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis? Eur. Respir. J. 2008; 31: 904–910.
(check this in PDF content)
17
Вernardo J., Yew W.W.How are ae creating fluoroquinolone-resistant tuberculosis? Am. J. Respir. Crit. Care Med. 2009; 180: 288–289.
(check this in PDF content)
18
Yoon Y.S., Lee H.J., Yoon H.I. Impact of fluoroquinolones on the diagnosis of pulmonary tuberculosis initially treated as bacterial pneumonia. Int. J. Tuberc. Lung Dis. 2005; 9 (11): 1215–1219.
(check this in PDF content)
19
Ginsburg A.S., Woolwine S.C., Hooper N. The rapid development of fluoroquinolone resistance in M. tuberculosis. N. Engl. J. Med. 2003; 349 (20): 1977–1978.
(check this in PDF content)
20
Migliori G.B., Eker B., Richardson M. et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in MDRTB. Eur. Respir. J. Express 2009.
(check this in PDF content)
21
Menzies D., Benedetti A., Paydar A. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med 2009; 6 (9): e1000146.
(check this in PDF content)
22
Lew W., Pai M., Oxlade O. Initial drug resistance and tuberculosis treatment outcomes: systematic review and metaanalysis. Ann. Intern. Med. 2008; 149 (2): 123–134.
(check this in PDF content)
23
World Health Organization. Anti-tuberculosis drug resistance in the world: fourth global report. Geneva, World Health Organization, 2008.
(check this in PDF content)
24
Faustini A., Hall A.J., Perucci C.A. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax 2006; 61 (2): 158–163. Информация об авторах Васильева Ирина Анатольевна– д. м. н., зав. отделом фтизиатрии
(check this in PDF content)